Compare Intuitive Surgical, Inc. (ISRG) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Xylem, Inc. — how do they compare? Intuitive Surgical, Inc. trades at $424.77 (market cap $146.76B), while Xylem, Inc. trades at $102.68 (market cap $23.81B). The key difference: Intuitive Surgical, Inc. is far larger — about 6.2× Xylem, Inc.'s market cap, and Xylem, Inc. pays a 1.69% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Xylem, Inc. for 50 Days on average.
| ISRG | XYL | |
|---|---|---|
Market Cap | $146.76B | $23.81B |
Volume | 2,529,814 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $592.85 | $152.95 |
52-Week Low | $332.02 | $100.92 |
Typical Hold Time | 84 Days | 50 Days |
Enterprise Value | $141.54B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $424.58, up 2.43% with strong bullish momentum. The stock shows robust fundamentals with revenue growing from $6.2B in 2022 to $10.1B in 2025 and net profit margins exceeding 28%. Recent earnings consistently beat expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast. Technical indicators show bullish moving averages with support at $410 and resistance at $419. Analyst consensus remains strongly positive with 70% buy ratings and a $480.78 price target.
ISRG maintains a dominant position in robotic surgery with expanding international growth offsetting China headwinds. The primary investment opportunity lies in continued procedure growth and da Vinci 5 adoption, though risks include competitive pressures and affordability concerns. With strong cash flow generation and institutional support, the stock presents upside potential despite premium valuations.
Xylem (XYL) trades at $102.20, up 0.36% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results due October 27, 2026. Revenue grew to $9.04B in 2025, with a net income margin of 10.59%, while recent acquisitions like Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
The outlook is supported by steady revenue growth and margin expansion, but risks include China weakness and higher debt from recent note offerings. Analyst consensus is mixed with a $149.13 price target, suggesting potential upside, though technical indicators caution near-term pressure. Investment appeal hinges on execution of growth strategies amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
